Open AccessASH2L is involved in promotion of endometrial cancer progression via upregulation of PAX2 transcription
Author(s) -
Zeng Kai,
Wu Yi,
Wang Chunyu,
Wang Shengli,
Sun Hongmiao,
Zou Renlong,
Sun Ge,
Song Huijuan,
Liu Wei,
Sun Ning,
Wei Shan,
Liu Wensu,
Su Yingjie,
Zhou Tingting,
Zhang Yi,
Zhao Yue
Publication year - 2020
Publication title -
cancer science
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 2.035
H-Index - 141
eISSN - 1349-7006
pISSN - 1347-9032
DOI - 10.1111/cas.14413
Subject(s) - endometrial cancer , biology , cancer research , transcription factor , gene knockdown , transactivation , carcinogenesis , histone , downregulation and upregulation , cancer , gene , genetics
Absent, small or homeotic 2‐like protein (ASH2L) is a core component of a multimeric histone methyltransferase complex that is involved in the maintenance of active transcription, participating in several cancers, however the biological function and molecular mechanism of ASH2L in endometrial cancer (ECa) are largely unknown. Endometrial cancer is a common malignant tumor in women and the incidence of this cancer is on the rise. Estrogen‐ERα signaling, as an oncogenic pathway, plays a crucial role in endometrial carcinogenesis. Therefore, further exploration of the molecular mechanisms around ERα‐mediated gene transcription in ECa would be helpful to the understanding of tumor development and to finding a new therapeutic target for ECa. Here, our study demonstrated that ASH2L was highly expressed in ECa samples, and higher expression of ASH2L was positively correlated with a poor prognosis. Moreover, we identified that ASH2L associated with ERα and that knockdown of ASH2L resulted in decreased expression of a subset of the estrogen‐induced target genes, including paired box 2 ( PAX2 ), an oncogenic gene in ECa. ASH2L was recruited to cis ‐regulatory elements in PAX2 , thereby altering histone H3K4me3 and H3K27me3 levels, to enhance ERα‐mediated transactivation. Finally, depletion of ASH2L suppressed endometrial cancer cell proliferation and migration. Our findings suggest that ASH2L participates in the promotion of ECa progression, if not totally at least partially, via upregulation of PAX2 transcription.